Patents Examined by John M Mauro
  • Patent number: 11110442
    Abstract: A process for preparing a molding comprising zinc and a titanium-containing zeolitic material having framework type MWW, comprising (i) providing a molding comprising a titanium-containing zeolitic material having framework type MWW; (ii) preparing an aqueous suspension comprising a zinc source and the molding comprising a titanium-containing zeolitic material having framework type MWW prepared in (i); (iii) heating the aqueous suspension prepared in (ii) under autogenous pressure to a temperature of the liquid phase of the aqueous suspension in the range of from 100 to 200° C., obtaining an aqueous suspension comprising a molding comprising zinc and a titanium-containing zeolitic material having framework type MWW; (iv) separating the molding comprising zinc and a titanium-containing zeolitic material having framework type MWW from the liquid phase of the suspension obtained in (iii).
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: September 7, 2021
    Inventors: Andrei-Nicolae Parvulescu, Ulrich Mueller, Hans-Juergen Luetzel, Joaquim Henrique Teles, Dominic Riedel, Daniel Urbanczyk, Ulrike Wegerle, Markus Weber, Nicolai Tonio Woerz, Christian Mueller
  • Patent number: 11103479
    Abstract: This invention provides small organic molecules useful as therapeutics of neurodegenerative diseases. Small organic molecules that act as inhibitors of bone morphogenetic proteins (BMPs) are useful in the treatment of neuroinflammatory disorders, in particular multiple sclerosis.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: August 31, 2021
    Assignee: THE MEDICAL RESEARCH, INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER
    Inventors: Arnon Karni, Karin Bernadet Fainberg
  • Patent number: 11104657
    Abstract: Compounds of formula (I) in the capacity of compounds with anti-tumor activity for the treatment of T-cell acute lymphoblastic leukemia (T-ALL).
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: August 31, 2021
    Assignees: FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA, UNIVERSITÀ DEGLI STUDI DI ROMA “LA SAPIENZA”
    Inventors: Bruno Botta, Isabella Screpanti, Luca Tottone, Nadezda Zhdanoskaya, Cinzia Ingallina, Francesca Giulimondi, Deborah Quaglio, Rocco Palermo, Mattia Mori, Francesca Ghirga
  • Patent number: 11103504
    Abstract: A method of killing bacteria and an antibiotic kit are provided herein. The method includes treating the bacteria with a DNA condensation-inducing compound; and subsequently treating the bacteria with an Eis inhibitor. The kit includes a DNA condensation-inducing compound packaged together with an Eis inhibitor.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: August 31, 2021
    Assignees: University of Kentucky Research Foundation, Academisch Medisch Centrum
    Inventors: Sylvie Garneau-Tsodikova, Nicole Neeltje van der Wel
  • Patent number: 11098058
    Abstract: The invention provides novel compounds having the general formula I: wherein R1, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: August 24, 2021
    Assignee: Genentech, Inc.
    Inventors: Snahel Patel, Gregory Hamilton, Guiling Zhao, Huifen Chen, Blake Daniels, Craig Stivala
  • Patent number: 11091459
    Abstract: The present invention relates to compositions comprising the compound niraparib, in particular certain solid forms of niraparib.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: August 17, 2021
    Assignees: Tesaro, Inc., Merck Sharp & Dohme Corp.
    Inventors: George Wu, John Chaber, Arlene E. McKeown, Jennifer R. Foley
  • Patent number: 11078201
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: August 3, 2021
    Assignee: Nimbus Saturn, Inc.
    Inventors: Neelu Kaila, Ian Linney, Stuart Ward, Grant Wishart, Ben Whittaker, Alexandre Cote, Jeremy Robert Greenwood, Abba Leffler, Steven K. Albanese, Daniel L. Severance
  • Patent number: 11066391
    Abstract: The present invention relates to bifunctional compounds that induce HMG-CoA reductase degradation, in which in which atorvastatin and E3 ubiquitin ligase binding moiety are chemically linked. The present invention also relates to a preparation method of the compounds, a method for degrading HMG-CoA reductase using the compounds, and a composition for the prevention or treatment of HMG-CoA reductase-related diseases comprising the compounds.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: July 20, 2021
    Assignee: UPPTHERA
    Inventors: Soo Hee Ryu, Hwa Jin Lee, Seong Hoon Kim, Hye Guk Ryu, Eun Bin Lee
  • Patent number: 11059786
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I and Formula III, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: July 13, 2021
    Assignee: CORTEXYME, INC.
    Inventors: Andrei W. Konradi, Robert A. Galemmo, Jr., Casey C. Lynch
  • Patent number: 11052066
    Abstract: This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, Dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring-wound healing abnormalities, post-operative adhesions, and reactive fibrosis.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: July 6, 2021
    Assignee: Corbus Pharmaceuticals, Inc.
    Inventors: Mark Tepper, Dean A. Frey, David Goeddel, Karl E. Reineke
  • Patent number: 11040972
    Abstract: Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with autotaxin activity. The methods and compositions disclosed herein include the use of at least one autotaxin inhibitor compound.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: June 22, 2021
    Assignee: SICHUAN HAISCO PHARMACEUTICAL CO., LTD.
    Inventors: Bohan Jin, Qing Dong, Gene Hung, Yao Li
  • Patent number: 11040334
    Abstract: Provided is a catalyst for reduction reaction with which 1,4-butanediol or tetrahydrofuran can be obtained with higher selectivity than with the related art, using a raw material derived from biomass. The catalyst is used in a reduction reaction of 3,4-dihydroxytetrahydrofuran with hydrogen, wherein the catalyst contains metal catalysts (1) and (2) below; metal catalyst (1): a catalyst containing M1 and M2 below as metal species and supported on a carrier; and metal catalyst (2): a catalyst containing M1 below as a metal species and supported on a carrier; M1: one or more selected from the group consisting of iron and elements belonging to periods 4 to 6 and groups 5 to 7 of the periodic table; and M2: one or more selected from the group consisting of ruthenium, osmium, and elements belonging to periods 4 to 6 and groups 9 to 11 of the periodic table.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: June 22, 2021
    Assignee: DAICEL CORPORATION
    Inventors: Keiichi Tomishige, Yoshinao Nakagawa, Masazumi Tamura, Yuuichirou Hirai, Yasuteru Kajikawa, Keisuke Ono
  • Patent number: 11040944
    Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: June 22, 2021
    Assignee: Curasen Therapeutics, Inc.
    Inventors: Anthony P. Ford, Wei Chen, David Scott Carter, Jiaxin Yu
  • Patent number: 11034667
    Abstract: Selective HDAC inhibitors, and pharmaceutical compositions that include the same, are described herein for the treatment of cancer, immunological diseases, inflammatory diseases, and neurological diseases.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: June 15, 2021
    Assignee: Shuttle Pharmaceuticals, Inc.
    Inventors: Scott Grindrod, Mira Jung, Milton Brown, Anatoly Dritschilo
  • Patent number: 11027263
    Abstract: Disclosed is an oxidation process to produce a crude carboxylic acid product carboxylic acid product. The process comprises oxidizing a feed stream comprising at least one oxidizable compound to generate a crude carboxylic acid slurry comprising furan-2,5-dicarboxylic acid (FDCA) and compositions thereof. Also disclosed is a process to produce a dry purified carboxylic acid product by utilizing various purification methods on the crude carboxylic acid.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: June 8, 2021
    Assignee: Eastman Chemical Company
    Inventors: Mesfin Ejerssa Janka, Kenny Randolph Parker, Ashfaq Shahanawaz Shaikh, Lee Reynolds Partin
  • Patent number: 11028082
    Abstract: The present invention relates to a process for the preparation of a novel and versatile synthesis intermediate and its use in the preparation of umeclidinium. The invention also relates to some reference standards allowing to detect impurity traces recurring in the preparation of umeclidinium and a process for their preparation.
    Type: Grant
    Filed: May 28, 2018
    Date of Patent: June 8, 2021
    Assignee: OLON S.P.A.
    Inventors: Giorgio Bertolini, Corrado Colli, Filippo Nisic, Mara Sada, Stefania Bertuolo, Silvano Ronzoni, Stefano Maiorana, Romano Di Fabio
  • Patent number: 11021492
    Abstract: Novel rapamycin analogs and uses thereof are disclosed herein. The rapamycin analogs of the present disclosure show increased mTORC1 specificity and lowered mTORC2 specificity relative to rapamycin.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: June 1, 2021
    Assignee: AEOVIAN PHARMACEUTICALS, INC.
    Inventors: Stelios T. Tzannis, Ian J. Massey, Alexandre Froidbise, Guillaume Eppe
  • Patent number: 11021489
    Abstract: Disclosed herein are polycyclic aromatic compound embodiments and methods of making and using such compounds. In some embodiments, the polycyclic aromatic compounds comprise an indenoindenodi(benzothiophene) skeleton. The polycyclic aromatic compound embodiments can be used in a variety of devices, such as electronic and/or electrooptical devices.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: June 1, 2021
    Assignee: University of Oregon
    Inventors: Michael Haley, Justin Dressler, Joshua Barker
  • Patent number: 11021471
    Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting the growth of gram-negative bacteria. Furthermore, the subject compounds and compositions are useful for the treatment of bacterial infection, such as urinary tract infection and the like.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: June 1, 2021
    Assignee: FORGE THERAPEUTICS, INC.
    Inventors: Min Teng, Baskar Nammalwar, Konstantin Taganov, Xiaoming Li, David T. Puerta
  • Patent number: 11014903
    Abstract: A vitamin E production method and a vitamin E production device which can highly purify vitamin E in a vitamin E concentrated fraction are provided. A raw oil supply section supplies a raw oil to a series column in which two or more columns including a strongly basic anion exchanger are coupled in series to adsorb vitamin E included in the raw oil on the strongly basic anion exchanger of at least one column from among the series column. A desorption solution supply section supplies a desorption solution to a column on which vitamin E has been adsorbed to desorb vitamin E from the strongly basic anion exchanger of the column.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: May 25, 2021
    Assignee: PHYTOCHEM PRODUCTS INC.
    Inventors: Naomi Kitakawa, Kousuke Hiromori, Sayaka Hosokawa, Tomoya Watanabe